search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


TRIAL Relapsed AML 2001/01.


- candidate number1226
- NTR NumberNTR136
- ISRCTNISRCTN94206677
- Date ISRCTN created20-dec-2005
- date ISRCTN requested18-okt-2005
- Date Registered NTR23-aug-2005
- Secondary IDsN/A 
- Public TitleTRIAL Relapsed AML 2001/01.
- Scientific TitleA randomised phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia (AML).
- ACRONYMRelapsed AML 2001/01
- hypothesisAddition of liposomal daunorubicin (DaunoXomeŽ) to FLAG in the first reinduction course will result in improved treatment response with acceptable toxicity and without increased cardiotoxicity.
- Healt Condition(s) or Problem(s) studiedAcute Myeloid Leukemia (AML)
- Inclusion criteria1. Primary refractory AML;
2. First relapsed AML;
3. 2nd or subsequent relapsed AML, but not previously treated according to protocol Relapsed AML 2001/01;
4. <18 years of age at initial diagnosis;
5. Signed informed consent.
- Exclusion criteria1. Symptomatic cardiac dysfunction (CTC grade 3 or 4), and/or a fractional shortening at echocardiography below 29%;
2. Karnofsky performance status <40% (children aged 16 years and older) or Lansky performance status of <40% (yougner children);
3. Any other organ dysfunction (CTC grade 4) that will interfere with the protocol treatment;
4. Inability to apply to the protocol for other reasons;
5. AML FAB type M3, acute promyelocytic leukemia, and/or t(15;17) and/or PML-RARalfa fusion gene.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 11-jan-2001
- planned closingdate11-jan-2007
- Target number of participants400
- InterventionsAddition of liposomal daunorubicin (DaunoXomeŽ) to FLAG in reinduction course I.
- Primary outcomePercentage of BM blasts >20% after course I, determined 4-6 weeks after the start.
- Secondary outcome1. Toxicity, focussing on but not limited to bone marrow aplasia, mucosal toxicity and cardiotoxicity;
2. Efficacy as determined by day 14 BM blasts, time to PB clearance of blasts, CR rate after 2 course of chemotherapy, % of patients that underwent SCT, overall survival, event-free survival and disease-free survival;
3. Clinical and cell biological features, and overall outcome of the entire cohort of patients with relapsed AML that has been registered in the time period of patient accrual (also including patients that were not treated according to this protocol).
- TimepointsN/A
- Trial web siteN/A
- statusinclusion stopped: follow-up
- CONTACT FOR PUBLIC QUERIESDr. Gertjan J.L. Kaspers
- CONTACT for SCIENTIFIC QUERIESDr. Gertjan J.L. Kaspers
- Sponsor/Initiator Dutch Childhood Oncology Group (DCOG)
- Funding
(Source(s) of Monetary or Material Support)
[default]
- PublicationsN/A
- Brief summaryRelapsed and refractory acute myeloid leukemia (AML) in children is a rare problem, but has a poor prognosis.
We therefore designed an international multicenter open label randomised phase III trial in children with such a disease.
Reinduction treatment will be done with 2 courses of combination chemotherapy, with FLAG (fludarabine, ara-C and G-CSF) in both courses as standard treatment. In the first course there will be a randomisation for liposomal daunorubicin (DaunoXomeŽ) to be added or not. The second course should always concern FLAG.
If patients have >20% of blasts in the bone marrow after the 1st course, or if they are not in complete remission (CR) after the 2nd course, they will go off protocol.
Patients in CR after reinduction treatment can immediately proceed to stem cell transplantation. Consolidation chemotherapy should be given if SCT is delayed. A 3rd course of intensive chemotherapy (VP16 and continuous infusion with cytarabine) is the general recommendation. In selected patients, a low intensity consolidation may be preferred, and such a schedule is described as well.
The type of SCT is based on the risk-group. Preferably, a matched sibling donor (MSD) SCT is performed. If a MSD is not available all patients are candidates for a matched unrelated donor (MUD) SCT. If a MUD is also not available, patients with primary refractory disease, early relapse (within 1 year from diagnosis), or 2nd or higher relapse, are candidates for the more experimental haplo-identical donor (HID) SCT in view of the dismal prognosis. However, patients with a late relapse (>1 year from initial diagnosis) have a better prognosis and should be offered an autologous SCT if a MSD or MUD SCT is not possible. Only in case of autologous SCT, maintenance treatment and/or adjuvant immunotherapy could be considered.

Main objectives of the study:
are to determine the efficacy and toxicity of DaunoXomeŽ when added to FLAG in children with relapsed and refractory AML. In addition, the study will prospectively determine the clinical outcome of these patients, stratified according to the different risk groups (refractory disease, early relapse, late relapse, multiple relapse).

Additional objectives:
are to determine the clinical relevance of minimal residual measurements, in vitro cellular drug resistance data, cell biological and molecular features and pharmacokinetic data of DaunoXomeŽ, in these patients.

The study expects to accrue up to 100 patients annually, and will run about 4 years, to enroll a total of 360 randomised patients.
- Main changes (audit trail)
- RECORD16-aug-2005 - 10-nov-2010


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl